Key facts
- This page summarizes Gregory Knutson's Form 4 filing for U.S. Stem Cell, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Apr 2022, 16:28.
Gregory Knutson - 25 Apr 2022 Form 4 Insider Report for U.S. Stem Cell, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 25 Apr 2022
- Net transaction value
- +$10,000
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2022, 16:28:21 UTC
- Prior SEC filing
- 25 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Knutson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory Knutson filed Form 4 for U.S. Stem Cell, Inc. on 29 Apr 2022.
Change
- Previous filing in this sequence was filed on 25 Mar 2022.
- Current net transaction value: +$10,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
USRM
transaction
Common Stock
Award
- Transaction value
- $10,000
- Shares
- +2,500,000
- Change %
- +9.4%
- Price
- $0.004000
- Shares after
- 29,175,000
- Date
- 25 Apr 2022
- Ownership
- Direct
USRM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 38,005,331
- Date
- 25 Apr 2022
- Ownership
- Held by NorthStar Biotech Group, LLC of which Gregory Knutson is Managing Director
* marks a reported price that did not pass the local price check.